Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward Ltd. director Miriam Kidron filed an initial ownership report on Form 3. This filing establishes her status as a director and confirms that there are no reportable stock or option transactions included. It is an administrative disclosure required when someone becomes an insider of a public company.
Lifeward Ltd. completed its acquisition of Oratech Pharma in accordance with a prior share purchase agreement. At closing, it issued an aggregate 2,256,476 of its ordinary shares and pre-funded warrants, plus 1,296,296 additional warrants to Oramed and agreed to future revenue-sharing on ReWalk Personal Exoskeleton sales and related extended warranties.
To fund the transaction structure, Lifeward also issued $10,000,000 aggregate principal amount of senior secured convertible notes with accompanying warrants under an existing securities purchase agreement, in a private offering to accredited investors under Regulation D exemptions. Two Class II directors resigned without disagreement, and the board expanded from five to eight members with three new directors appointed and committee compositions updated.
Lifeward Ltd. reported that Nasdaq has notified the company it is no longer in compliance with the Nasdaq audit committee rule requiring at least three members. The non-compliance arose after director Hadar Levy resigned, leaving only two audit committee members.
The company is evaluating options to restore compliance within Nasdaq’s cure period, which runs until the earlier of its next annual shareholder meeting or February 24, 2027, subject to an August 24, 2026 deadline if the next annual meeting is held before that date. Lifeward’s ordinary shares will continue trading on the Nasdaq Capital Market under the symbol LFWD, and the notice has no immediate effect on the listing.
Lifeward Ltd. reports its 2025 annual business overview as a specialized neurorehabilitation and mobility medical device company. The company sells ReWalk powered exoskeletons for spinal cord injury, ReStore soft exo-suits for stroke rehab, and AlterG Anti-Gravity systems used in over 6,000 facilities globally.
Lifeward highlights U.S. and European reimbursement progress, including Medicare’s brace benefit classification for personal exoskeletons and a final DMEPOS fee schedule amount of $91,032 per device under HCPCS code K1007. Veterans Health Administration policies and German statutory insurer contracts continue to support case-by-case coverage.
Strategically, Lifeward agreed to acquire Oratech Pharma from Oramed in a share and warrant deal that will give Oramed up to 49.99% of Lifeward’s fully diluted equity and 4% revenue sharing on ReWalk products, alongside up to $20.0 million of senior secured convertible notes and high-interest bridge loans. Additional moves include a Skelable IP acquisition for upper-limb robotics and new distribution agreements with CorLife for U.S. workers’ compensation and Verita Neuro for select international markets.
Lifeward Ltd. reported fourth quarter and full-year 2025 results while advancing a major strategic shift toward diversified biomedical innovation. Full-year 2025 revenue was $22.0 million, down from $25.7 million in 2024, but GAAP net loss narrowed to $19.9 million from $28.9 million as operating expenses fell 25%.
Fourth-quarter 2025 revenue was $5.1 million versus $7.5 million a year earlier, with lower AlterG and MyoCycle sales partly offset by stronger ReWalk exoskeleton revenue. Lifeward secured shareholder approval for a transformative Oramed transaction, under which Oramed may own up to 49.99% of Lifeward and provide up to $47 million in funding while contributing its POD™ oral protein delivery platform. The company also agreed to acquire a powered upper-body exoskeleton, targeting commercial launch in roughly 18–24 months. Cash and cash equivalents were $2.2 million as of December 31, 2025.
Lifeward Ltd. reported the results of its extraordinary shareholder meeting held on March 12, 2026. Shareholders representing 7,252,783 ordinary shares, about 39.7% of the 18,293,776 shares outstanding as of January 20, 2026, were present or voted, forming a quorum.
Investors approved issuing ordinary shares to Oramed Pharmaceuticals Inc. for the acquisition of 100% of Oratech Pharma, Inc., and related warrants and convertible note issuances tied to that deal. They also approved electing two external directors effective at the Oratech closing, their compensation framework, increasing shares under the 2025 Incentive Compensation Plan, and an equity grant to CEO Mark Grant.
Shareholders further approved reappointing Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent auditor for the year ending December 31, 2026, with the board authorized to set its remuneration.
Lifeward Ltd. reported that it has regained compliance with Nasdaq’s minimum bid price listing standard. The company received written notice from Nasdaq’s Listing Qualifications Hearings Department confirming that its Ordinary Shares met the $1.00 per share minimum closing bid price for 10 consecutive business days from February 24, 2026 to March 9, 2026. Nasdaq stated that the minimum bid price matter is now closed, meaning Lifeward’s Ordinary Shares continue to qualify for listing on the Nasdaq Capital Market.
Lifeward Ltd. implemented a 1-for-12 reverse share split of its ordinary shares effective February 24, 2026. The move is intended to help the company meet the $1.00 minimum bid price required to keep its Nasdaq Capital Market listing.
The reverse split reduced issued and outstanding ordinary shares from 18,339,098 to approximately 1,528,098, while the company’s authorized ordinary shares increased from 75,000,000 to 100,000,000 under its Eighth Amended and Restated Articles of Association. No fractional shares were issued, with holdings rounded down to the nearest whole share, and the shares now trade on a split-adjusted basis under the existing symbol LFWD.
Lifeward Ltd. reported a change in its Board of Directors. On February 24, 2026, Class I director Hadar Levy notified the Board of his decision to step down, effective the same day. The company stated that his departure was not due to any disagreement regarding operations, policies or practices, and expressed gratitude for his service and contributions.
Lifeward Ltd. entered into an Intellectual Property Assignment and Technology Transfer Agreement with Skelable Ltd. on February 19, 2026. Lifeward will acquire specified intellectual property and related technology assets and bring certain key Skelable employees on board under new employment agreements.
As consideration, Lifeward will pay up to $500,000 in three milestone-based installments, with $480,000 payable in ordinary shares and $20,000 in cash. The shares will be priced at the higher of the prior trading day’s closing price or the daily volume-weighted average price. These shares will be issued as an unregistered offering relying on the Section 4(a)(2) exemption under the Securities Act of 1933. The initial closing of the transaction is expected to occur in the near future, subject to customary conditions.